The authors make no claims of the accuracy of the information contained
herein; and these suggested doses and/or guidelines are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the
preparation of this document shall be liable for any special,
consequential, or exemplary damages resulting in whole or part from any
user's use of or reliance upon this material. PLEASE
READ THE DISCLAIMER CAREFULLY BEFORE
ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE
TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.
Standard Dilutions [Amount of drug]
[Infusion volume] [Infusion rate]
[1 to 3 mg/ 50 ml] [30 min]
[4 to 10 mg/ 100 ml] [As directed]
Label: Do not Refrigerate.
Actions: Marked sedation/ antiemetic.
Cases of QT prolongation and/or torsade de pointes have been
reported in patients receiving droperidol at doses at or below
recommended doses. Some cases have occurred in patients with no
known risk factors for QT prolongation and some cases have been
Due to its potential for serious proarrhythmic effects and
death, droperidol should be reserved for use in the treatment
of patients who fail to show an acceptable response to other
adequate treatments, either because of insufficient
effectiveness or the inability to achieve an effective dose due
to intolerable adverse effects from those drugs (see Warnings,
Adverse Reactions, Contraindications, and Precautions).
Cases of QT prolongation and serious arrhythmias (e.g., torsade
de pointes) have been reported in patients treated with
droperidol. Based on these reports, all patients should undergo
a 12-lead ECG prior to administration of droperidol to
determine if a prolonged QT interval (i.e., QTc greater than
440 msec for males or 450 msec for females) is present. If
there is a prolonged QT interval, droperidol should NOT be
administered. For patients in whom the potential benefit of
droperidol treatment is felt to outweigh the risks of
potentially serious arrhythmias, ECG monitoring should be
performed prior to treatment and continued for 2-3 hours after
completing treatment to monitor for arrhythmias.
Droperidol is contraindicated in patients with known or
suspected QT prolongation, including patients with congenital
long QT syndrome.
Droperidol should be administered with extreme caution to
patients who may be at risk for development of prolonged QT
syndrome (e.g., congestive heart failure, bradycardia, use of a
diuretic, cardiac hypertrophy, hypokalemia, hypomagnesemia, or
administration of other drugs known to increase the QT
interval). Other risk factors may include age over 65 years,
alcohol abuse, and use of agents such as benzodiazepines,
volatile anesthetics, and I.V. opiates. Droperidol should be
initiated at a low dose and adjusted upward, with caution, as
needed to achieve the desired effect.
DOSAGE AND ADMINISTRATION
Dosage should be individualized. Some of the factors to be considered
in determining dose are age, body weight, physical status, underlying
pathological condition, use of other drugs, the type of anesthesia to
be used, and the surgical procedure involved.
Vital signs and ECG should be monitored
Adult Dosage: The maximum recommended initial dose of
droperidol is 2.5 mg I.M. or slow I.V. Additional 1.25 mg doses of
droperidol may be administered to achieve the desired effect. However,
additional doses should be administered with caution, and only if the
potential benefit outweighs the potential risk.
Pediatric Dosage: For children two to 12 years of age,
the maximum recommended initial dose is 0.1 mg/kg, taking into account
the patient’s age and other clinical factors. However, additional doses
should be administered with caution, and only if the potential benefit
outweighs the potential risk.
See WARNINGS for use of droperidol with other CNS depressants and in
patients with altered response.
Parenteral drug products should be inspected visually for particulate
matter and discoloration prior to administration, whenever solution and
container permit. If such abnormalities are observed, the drug should
not be administered.
Premedication: 2.5 to 10mg IV / IM. Usually 1.25 to 2.5 mg q3-6h prn.
Continuous infusion: 25 mg/500 ml D5W at 1 mg/hr
initially for treatment of hyperemesis gravidarum (give 1 to 2.5 mg
loading initially). May increase by 0.25 mg at 4hr intervals if
patient not responding (usual range: 1 to 1.25 mg/hr). Also add
benadryl 50mg q6h until infusion is stopped. When patient is ready to
take oral meds switch to reglan 10mg qid + hydroxyzine 50mg.
Droperidol Injection, USP 2.5 mg/mL is supplied in 2 mL (5 mg)
single-dose ampuls packaged in cartons of ten (List No. 1187).
Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room
Protect from light.
The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical
judgment. Neither GlobalRPh Inc. nor any other party involved in the
preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER
BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU
AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.